Conclusions

In this review we intend to present the current state of knowledge regarding the EndoMT process which occurs not only during embryonic development but also in the pathogenesis of various diseases that take place not only in adult life but also throughout childhood and adolescence. In other words, we provides an excellent example of how the morphogenesis is recapitulated at least in part, in vascular pathologies, repair of injured tissues and during tumor progression.

Finally, as it has been proposed by other authors, we believe that the EndoMET would represent a therapeutic target in atherosclerosis, tumor angiogenesis, and other disorders[10,11,16].

References

1. Hahn C, Schwartz MA. Mechanotransduction in vascular physiology and atherogenesis. Nat Rev 2009; 10: 53-62.
2. Davies PF. Hemodynamic shear stress and the endothelium in cardiovascular pathophysiology. Nat Clin Pract Cardiovasc Med 2009; 6: 16-26.
3. Stewart S, Rassl D. Advances in the understanding and classification of pulmonary hipertension. Histophatology 2009; 54: 104-116.
4. Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, MacLean MR et al. Cellular and molecular basis of pulmonary arterial hipertension. J Am Coll Cardiol 2009; 54: S20-S31.
5. Nakashima Y, Xiang Cheng Y, Kinukawa N, Sueishi K. Distributions of diffuse intimal thickening in human arteries: Preferencial expresion in atherosclerosis-prone arteries from an early age. Virchows Arch 2002; 441: 279-88.
6. Nakashima Y, Wight TN, Sueishi K. Early atherosclerosis in humans: Role of diffuse intimal thickening and extracellular matrix proteoglycans. Cardiovasc Res. 2008; 79: 14-23.
7. Majesky MW. Developmental basis of vascular smooth muscle diversity. Arterioscler Thromb Vasc Biol 2007; 27: 1-11.
8. Hoofnagle MH, Thomas JA, Wamboff BR, Owens G. Origin of neointimal smooth muscle: We`ve come full circle. Arterioscler Thromb Vasc Biol 2006; 26: 2579-2581.
9. Sata M, Saiura A, Kunisato A, Tojo A, Okada S, Tokuhisa T et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 2002; 8: 403-409.
10. Arciniegas E, Frid MG, Douglas IS, Stenmark KR. Perspectives on endothelial-to-mesenchymal transition: potential contribution to vascular remodeling in chronic pulmonary hipertension. Am J Physiol Lung Cell Mol Physiol 2007; 293: L1-L8.
11. Goumans MJ, van Zonneveld AJ, Dijke PT. Transforming growth factor β-induced endothelial-to-mesenchymal transition: A switch to cardiac fibrosis? Trends Cardiovasc Med 2008; 18: 293-298.
12. Kitao A, Sato Y, Kitamura SS, Harada K, Sasaki M, Morikawa H, et al. Endothelial to mesenchymal transition via transforming growth factor-β1/ smad activation is associated with portal venous stenosis in idiopathic portal hipertension. Am J Pathol 2009; 175: 616-626.
13. Mironov V, Visconti RP, Markwald RR. On the role of shear stress in cardiogenesis. Endothelium 2005; 12: 259-261.
14. Xi-Qiao W, Ying-Kai L, Chun Q, Shu-Liang L. Hyperactivity of fibroblasts and functional regression of endothelial cells contributes to microvessel occlusion in hypertrophic sparring. Microvasc Res 2009; 77: 204-211.
15. Zeisberg EM, Potenta SE, Sugimoto H, Zeisberg M, Kalluri R. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol 2008; 19: 2282-2287.
16. Potenta S, Zeisberg E, Kalluri R. The role of endothelial-to-mesenchymal transition in cancer progression. British J Cancer 2008; 99: 1375-1379.
17. Baum B, Settleman J, Quinlan MP. Transitions between epithelial and mesenchymal states in development and disease. Seminar Cell Dev Biol 2008; 19: 294-308.
18. Dejana E, Orsenigo F, Lampugnani MG. The role of adherens junctions and VE-cadherin in the control of vascular permeability. J Cell Sci 2008; 121: 2115-2122.
19. Dejana E, Lasserve ET, Weinstein BM. The control of vascular integrity by endothelial cell junctions: Molecular basis and pathological implications. Dev Cell 2009; 16: 209-221
20. Mukherjee S, Tessema M, Wandinger-Ness A. Vesicular trafficking of tyrosine kinase receptors and associated proteins in the regulation of signaling and vascular function. Circ Res 2006; 98: 743-756.
21. Frid MG, Kale VA, Stenmark KR. Mature vascular endothelium can give rise to smooth muscle cells via endothelial mesenchymal transdifferentiation: in vitro analysis. Circ Res 2002; 90; 1189-1196.
22. Liebner S, Catellino A, Gallini R, Rudini N, Iurlaro M, Piccolo S, et al. β-catenin is required for endothelial-mesenchymal transformation during heart cushion development in the mouse. J Cell Biol 2004; 166: 359-367.
23. Arciniegas E, Neves YC, Carrillo LM. Potential role for insulin-like growth factor II and vitronectin in the endothelial-mesenchymal transition process. Differentiation 2006; 74: 277-292.
24. Arciniegas E, Candelle D. An alternate insulin-like factor I receptor signaling pathway for the progression of endothelial-mesenchymal transition. Bioscience Hypotheses 2008; 1: 312-319.
25. Perks CM, Holly JM. The insulin-like growth factor (IGF) family and breast cancer. Breast Dis 2009; 18: 45-60.
26. Chao W, D' Amore PA. IGF2: Epigenetic regulation and role in development and disease. Cytokine Growth Factor Rev. 2008; 19: 111-120.
27. 16 Zaina S, Nilsson J. Insulin-like growth factor II and its receptors in atherosclerosis and in conditions predisposing to atherosclerosis. Curr Opin Lipidol 2003; 14: 483-489.
28. Hsu E, Feghali-Bostwick, CA. Insulin-like growth factor-II is increased in systemic sclerosis-associated pulmonary fibrosis and contributes to the fibrotic process via Jun N-terminal kinase and phosphatidylinositol-3 kinase dependent pathways. Am J Pathol 2008; 172: 1580-1590.
29. Louvi A, Accili D, Efstratiadis A. Growth promoting interaction of IGF-II with the insulin receptor during mouse embryonic development. Dev Biol 1997; 189: 33-48.
30. Arciniegas E, Carrillo LM, De Sanctis JB, Candelle D. Possible role of NFκB in the embryonic vascular remodeling and the endothelial mesenchymal transition process. Cell Adhesion & Migration 2008; 2: 1-13.
31. Sun HW, Li CJ, Chen, HQ, Lin HL, Lv HX, Zhang M. Involvement of integrins, MAPK and NF-kB in regulation of the shear stress-induced MMP-9 expression in endothelial cells. Biochem Biophys Res Commun 2007; 353: 152-158.
32. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J 2000; 19: 3159-3167.
33. Schneider MR, Wolf E. The epidermal growth factor receptor ligands at a glance. J Cell Physiol 2009; 218: 460-466.

34. Lin SY, Makino K, Xia W, Matin A, Wen Yong, Kwong KY et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 2001; 3: 802-808.

35. Feigin ME, Muthuswamy SK. ErbB receptors and cell polarity: New pathways and paradigmas for understanding cell migration and invasion. Exp Cell Res 2009; 315: 707-716.

36. De Luca A, Carotenuto A, Rachiglio A, Gallo M, Maiello MR, Aldinucci D, et al. The role of the EGFR signaling in tumor microenvironment. J cell Physiol 2008; 214: 559-567.

37. Ackland ML, Newgreen DF, Fridman M, Watham MC, Arvanitis A, Minichiello J, et al. Epidermal growth factor induced epithelio-mesenchymal transition in human breast carcinoma cells. Lab Invest 2003; 83: 435-448.

38. Beltowski J, Lowicka E. EGF receptor as a drug target in arterial hypertension. Mini Rev Med Chem 2009; 9: 526-538.

39. Sethi G, Ahn KS, Chaturvedi MM, Aggarwal BB. Epidermal growth factor (EGF) activates nuclear factor-kB through IkBα kinase-independent but EGF receptor-kinase dependent tyrosine 42 phosphorylation of IkBα. Oncogene 2007; 26: 7324-7332.

40. Dreux AC, Lamb DJ, Modjtahedi H, Ferns GA. The epidermal growth factor receptors and their family of ligands: Their putative role in atherogenesis. Atherosclerosis 2006; 186: 38-53.

41. Zhang H, Sunnarborg SW, McNaughton K, Johns TG, Lee DC, Faber JE. Heparin-binding epidermal growth factor-like growth factor signaling in flow-induced arterial remodeling. Circ Res 2008; 102: 1275-1285.

42. Camenisch TD, Schroeder JA, Bradley J, Klewer SE, McDonald JA. Heart valve mesenchyme formation is dependent on hyaluronan-augmented activation of ErbB2-ErbB3 receptors. Nat Med 2002; 8: 850-855.

43. Anderson-Berry A, O´Brien EA, Bleyl S, Lawson A, Gundersen N, Ryssman D, et al. Vasculogenesis drives pulmonary vascular growth in the developing chick embryo. Dev Dyn 2005; 233: 145-153.

44. Simons M. VEGF and restenosis: The rest of the story. Arterioscler Thromb Vasc Biol. 2009; 29: 439-440.

45. Wu Y, Zhu Z. Vascular endothelial growth factor receptor-l, a therapeutic target in cancer, inflammation and other disorders. Curr Med Chem 2009; 16: 2890-2898.

46. Shay-Salit A, Shushy M, Wolfovitz E, Yahav H, Breviario F, Dejana E, et al. VEGF receptor 2 and the adherens junction as a mechanical transducer in vascular endothelial cells. PNAS 2002; 99: 9462-9467.

47. Yang AD, Camp ER, Fan F, Shen L, Gray MJ, Liu W, et al. Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells. Cancer Res 2006; 66: 46-51.